Catalog No.
Product Name
Application
Product Information
Citations
-
HDAC Inhibitor
NT376 is a potent and selective inhibitor of class-IIa Histone deacetylases (HDAC), demonstrating an IC50 value of 32 nM in HT-29 cells. It exhibits significant biological activity that supports its role in cancer research and the investigation of central nervous system disorders, including Alzheimer's and Huntington's diseases. NT376 serves as a valuable tool for studying the epigenetic regulation of gene expression and potential therapeutic pathways in these conditions. -
HDAC6 Inhibitor
HDAC6-IN-66 is a potent and selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 1.8 nM. This compound effectively induces acetylation of α-tubulin while preferentially impacting histone H3. HDAC6-IN-66 serves as a valuable tool for cancer research, facilitating studies on the role of HDAC6 in oncogenic processes and potential therapeutic interventions. -
HDAC6 Inhibitor
HDAC6-IN-9 is a potent and selective inhibitor of HDAC6, demonstrating IC50 values of 4.2 nM for HDAC6 and significantly lower values for HDAC1, HDAC3, HDAC8, and HDAC10. This compound exhibits notable anti-proliferative activity, making it a valuable tool for research in cancer biology and therapeutic development. Its selectivity enables investigations into the specific roles of HDAC6 in cellular processes and disease states. -
HDAC Inhibitor
HDAC-IN-45 is a small molecule inhibitor targeting histone deacetylases (HDACs), specifically demonstrating significant inhibition of HDAC1, HDAC2, and HDAC3 with IC50 values of 0.108 µM, 0.585 µM, and 0.563 µM, respectively. This compound exhibits pronounced anticancer activity and forms a hydrogen bond with the Y303 residue, which may contribute to its mechanism of action. HDAC-IN-45 is valuable for cancer research, particularly in studies focused on epigenetic regulation and therapeutic interventions in tumorigenesis. -
HDAC Inhibitor
4-Iodo-SAHA is an orally active inhibitor of class I and class II histone deacetylases (HDACs), demonstrating EC50 values of 1.1, 0.95, 0.12, 0.24, 0.85, and 1.3 μM across the Skbr3, HT29, U937, JA16, and HL60 cell lines, respectively. This compound exhibits significant potential for tumor growth inhibition and is valuable for cancer research applications, including the investigation of epigenetic regulation and therapeutic interventions in HDAC-related malignancies. -
HDAC Inhibitor
HDAC-IN-26 is a highly selective inhibitor of class I histone deacetylases (HDACs), exhibiting an EC50 value of 4.7 nM. This compound plays a crucial role in modulating gene expression by preventing the deacetylation of histones, thereby facilitating an open chromatin state. HDAC-IN-26 is valuable for research applications involving cancer biology, neurodegenerative diseases, and epigenetic regulation. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-1 is a selective dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), with IC50 values of 4 nM and 8.9 nM, respectively. This compound demonstrates significant potential in ameliorating cognitive impairment in an Aβ1–42-induced mouse model, making it a valuable tool in Alzheimer's disease research. Its ability to modulate both cholinergic and epigenetic pathways positions BChE/HDAC6-IN-1 as a promising candidate for studies focused on neurodegenerative disorders. -
HDAC2 Inhibitor
HDAC2-IN-1 is a competitive inhibitor of histone deacetylase 2 (HDAC2), demonstrating an IC50 of 0.5 μM. This orally active compound exhibits additional inhibitory effects on HDAC1 and HDAC8, with IC50 values of 1.61 μM and 0.98 μM, respectively. Its ability to penetrate the blood-brain barrier positions HDAC2-IN-1 as a valuable tool for investigating the role of HDACs in neurodegenerative diseases and other neurological disorders. -
HDAC6 Inhibitor
HDAC6-IN-52 is a potent inhibitor of histone deacetylase 6 (HDAC6), demonstrating a complete inhibition at 10 μM. This compound is significant in the context of central nervous system diseases, particularly neurodegenerative disorders such as Alzheimer’s disease and progressive supranuclear palsy. HDAC6-IN-52 is valuable for research investigating the therapeutic potential of HDAC6 modulation in neurological conditions. -
HDAC Inhibitor
HDAC-IN-20 is a potent inhibitor of histone deacetylases (HDACs), offering oral bioavailability. It exhibits significant anti-cancer activity, making it a valuable tool for investigating tumor biology and exploring epigenetic regulation in cancer research. This compound facilitates the study of HDAC's role in oncogenesis and therapeutic responses, thereby contributing to the understanding of cancer treatment strategies. -
HDAC6 Inhibitor
MPT0G413 is a selective HDAC6 inhibitor with an IC50 of 3.92 nM, demonstrating potent oral bioavailability and the ability to penetrate the blood-brain barrier. This compound effectively reduces tau protein phosphorylation and aggregation, thereby addressing cognitive deficits related to memory and learning. MPT0G413 is suitable for research applications in neurological disorders, including Alzheimer's disease. -
HDAC6 Inhibitor
NR160 is a selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 value of 30 nM. This compound demonstrates low cytotoxicity in leukemia cell lines and enhances the induction of apoptosis when used in conjunction with proteasome inhibitor Bortezomib, as well as chemotherapeutic agents Epirubicin and Daunorubicin. NR160 serves as a valuable tool for researchers investigating the therapeutic potential of HDAC6 inhibition in cancer treatment. -
Anti-inflammatory Peptide
SAP15 is a synthetic anti-inflammatory peptide derived from human beta-defensin 3, comprising 15 amino acids. This peptide effectively penetrates cells to downregulate intracellular inflammation by inhibiting the phosphorylation of HDAC5, which in turn reduces the phosphorylation of NF-κB p65. In LPS-induced macrophages, SAP15 demonstrates significant anti-inflammatory activity, while also enhancing the expression of aggrecan and type II collagen, and decreasing osteocalcin levels in LPS-induced chondrocytes. SAP15 serves as a valuable tool in the exploration of inflammation regulation and the development of anti-inflammatory therapies for biomaterials. -
PHD2/HDACs Inhibitor
PHD2/HDACs-IN-1 is a dual inhibitor targeting both PHD2 and various HDACs, demonstrating potent inhibitory activity with IC50 values of 1.15 μM for PHD2, 19.75 μM for HDAC1, 26.60 μM for HDAC2, and 15.98 μM for HDAC6. This compound showcases low toxicity and exhibits renoprotective effects, making it suitable for research related to cisplatin-induced acute kidney injury (AKI). Its ability to modulate epigenetic regulation and hypoxic signaling pathways positions it as a valuable tool in exploring the underlying mechanisms of renal stress responses. -
HDAC Inhibitor
YF479 is a potent inhibitor of histone deacetylases (HDACs), demonstrating significant biological activity in the modulation of gene expression. This compound impairs cell viability and suppresses both colony formation and tumor cell motility. Additionally, YF479 effectively inhibits breast tumor growth and metastasis, making it a valuable tool for research in breast cancer clinical trials. -
CYP17A1/HDAC6 Inhibitor
CYP17A1/HDAC6-IN-1 is a dual inhibitor targeting both CYP17A1 and HDAC6, exhibiting IC50 values of 0.284 μM and 0.6015 μM, respectively. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer biology. Its ability to simultaneously inhibit these targets suggests potential applications in therapeutic strategies against malignancies driven by steroidogenesis and histone deacetylation. -
HDAC8 Inhibitor
HDAC8-IN-2 is a potent inhibitor of histone deacetylase 8 (HDAC8) with IC50 values of 0.27 μM for Schistosoma mansoni HDAC8 and 0.32 μM for human HDAC8. This compound demonstrates significant efficacy in killing schistosome larvae and markedly reduces the egg-laying capacity of adult worm pairs. These properties make HDAC8-IN-2 a valuable tool for research focused on schistosomiasis and histone deacetylation processes. -
HDAC3 Inhibitor
HDAC3-IN-4 is a selective inhibitor of histone deacetylase 3 (HDAC3) with an IC50 of 89 nM, demonstrating effective targeting of this enzyme. It promotes the degradation of PD-L1 through the modulation of cathepsin B (CTSB) activity in lysosomes, exhibiting a DC50 of 5.7 μM. HDAC3-IN-4 shows high selectivity for HDAC3 compared to other HDAC isoforms, including HDAC1, HDAC6, HDAC7, and HDAC8, making it a valuable tool for studying epigenetic regulation and potential immunotherapeutic approaches. -
HDAC Inhibitor
FITC-SAHA is a fluorescein-conjugated derivative of SAHA, serving as a potent inhibitor of histone deacetylases (HDACs). This compound effectively modulates histone acetylation, influencing gene expression and cellular processes. FITC-SAHA is primarily utilized in cancer research and studies related to Alzheimer's disease, facilitating the investigation of HDAC's role in these conditions. Its fluorescent labeling aids in the visualization and analysis of cellular and molecular interactions. -
PfHDAC1 Inhibitor
HDAC1-IN-4 is a potent inhibitor of Plasmodium falciparum histone deacetylase 1 (PfHDAC1), demonstrating significant antimalarial activity with an IC50 of less than 5 nM. This compound exhibits a favorable safety profile with reduced cytotoxicity. HDAC1-IN-4 serves as a valuable tool for investigating the role of histone deacetylases in malaria research and may provide insights for novel therapeutic strategies against Plasmodium falciparum infections. -
PI3K/HDAC Inhibitor
PI3K/HDAC-IN-2 is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), demonstrating IC50 values of 226 nM for PI3Kα, 279 nM for PI3Kβ, 467 nM for PI3Kγ, and 29 nM for PI3Kδ. It also exhibits selective inhibition with IC50 values of 1.3 nM for HDAC1, 3.4 nM for HDAC2, 972 nM for HDAC4, 17 nM for HDAC6, and 12 nM for HDAC8. Due to its significant anticancer properties, PI3K/HDAC-IN-2 is valuable for research applications in cancer biology and therapeutic development. -
HDAC
Estrogen Receptor β/HDAC Probe 1 is a near-infrared fluorescent probe designed to simultaneously target the estrogen receptor β and histone deacetylase (HDAC). This probe enables the study of dynamic interactions between these two critical proteins, facilitating the investigation of their roles in cellular signaling and gene regulation. It is particularly useful in cancer research and other studies involving estrogen signaling pathways and epigenetic modifications. -
mTOR/HDAC Inhibitor
mTOR/HDAC-IN-1 is a dual inhibitor targeting mTOR and HDAC, exhibiting IC50 values of 0.49 nM and 0.91 nM for mTOR and HDAC1, respectively. This compound demonstrates significant anti-cancer activity, making it a valuable tool for research in cancer therapeutics and signaling pathways. Its selective inhibition profile offers potential for elucidating the roles of mTOR and HDAC in tumorigenesis and for developing novel cancer treatment strategies. -
HDAC3 Inhibitor
HDAC3-IN-T247 is a potent and selective inhibitor of HDAC3 (histone deacetylase 3), demonstrating an IC50 of 0.24 µM. This compound selectively enhances the acetylation of NF-κB in HCT116 cells, making it valuable for studies in cancer and viral pathogenesis. HDAC3-IN-T247 exhibits significant anticancer properties by inhibiting the proliferation of cancer cells and can also activate HIV gene expression in latently infected cells, thus serving as a useful tool for investigations in oncology and HIV research. -
HDAC2 Inhibitor
HDAC2-IN-2 is a selective inhibitor of histone deacetylase 2 (HDAC2), exhibiting a Kd value ranging from 0.1 to 1 μM. This compound is instrumental in studying the role of HDAC2 in various biological processes, including gene expression regulation and cell differentiation. Its inhibitory action makes it a valuable tool for researchers investigating epigenetic modifications and potential therapeutic targets in cancer and neurodegenerative diseases. -
LSD1/HDAC6/MAO-A Inhibitor
LSD1/HDAC6-IN-2 is a potent inhibitor targeting LSD1, HDAC6, and MAO-A, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. It demonstrates significant inhibitory effects on the growth of multiple myeloma cell lines, including MM.1S, MM.1R, and RPMI-8226. This compound is suitable for research applications focused on acute myeloid leukemia and lymphoma, providing insights into potential therapeutic mechanisms. -
HDAC3 Inhibitor
PT3 is a selective inhibitor of histone deacetylase 3 (HDAC3), demonstrating an IC50 value of 0.25 μM. This compound shows promising brain penetration capabilities and bioavailability following oral administration. PT3 is valuable for investigating the role of HDAC3 in neurodegenerative disorders, particularly in the context of Alzheimer’s disease research. -
HDAC Related
Ac-Arg-Gly-Lys(Ac)-AMC is a substrate specifically designed for the study of histone deacetylases (HDACs). It serves as a useful tool for measuring HDAC activity in various biological assays. This compound is instrumental in investigating the role of HDACs in cellular processes, as well as drug development related to cancer and other diseases where HDAC modulation may be therapeutic. -
HDAC3 Inhibitor
(E,E)-RGFP966 is a selective inhibitor of Histone Deacetylase 3 (HDAC3) that is capable of penetrating the central nervous system. This compound is particularly relevant for the investigation of neurodegenerative disorders, including Huntington's disease. Its specificity for HDAC3 makes it a valuable tool in studying the epigenetic regulation of gene expression and the accompanying mechanistic pathways involved in this condition. -
DNMT And HDAC Aual Inhibitor
DNMT/HDAC-IN-1 is a dual inhibitor targeting DNA methyltransferases (DNMT) and histone deacetylases (HDACs), demonstrating IC50 values of 56.84 nM for HDAC1 and 17.39 nM for HDAC6. This compound induces apoptosis in tumor cells and is valuable for cancer research applications, providing insights into the mechanisms of epigenetic regulation in malignancies. Its role in modulating both DNMT and HDAC activities makes it a significant tool for investigating therapeutic strategies in oncology. -
HDAC1 Inhibitor
HDAC1-IN-7 is a potent inhibitor of histone deacetylase 1 (HDAC1), exhibiting an IC50 of 0.957 mM. This compound serves as a valuable tool for investigating the role of HDAC1 in various biological processes, including gene expression regulation and cellular differentiation. Its application is relevant in studies of cancer biology and neurodegenerative disorders, where modulation of HDAC1 activity may provide insights into therapeutic strategies. -
HDAC11 Inhibitor
HDAC11-IN-2 is a selective inhibitor of Histone Deacetylase 11 (HDAC11), exhibiting an IC50 of 51.1 µM for HDAC11 and 5 µM for HDAC8. This compound effectively inhibits de novo lipogenesis and promotes fatty acid oxidation, addressing hepatic lipid accumulation and its associated pathological features in MASLD mouse models. Additionally, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at Thr172, further regulating metabolic pathways involved in lipid metabolism within the liver. -
HDAC6 Inhibitor
Bavarostat is a potent inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 17 nM, capable of crossing the blood-brain barrier. As a PET radiotracer, it can be labeled with 18F for in vivo mapping of HDAC6 distribution and assessing target occupancy in non-human primate models. Bavarostat selectively enhances tubulin acetylation without affecting histone acetylation, making it a valuable tool for research into neurodegenerative diseases, such as Alzheimer’s, as well as various cancers. -
PROTAC HDAC6 Degrader
HDAC6 Degrader-3 is a selective inhibitor that promotes the degradation of histone deacetylase 6 (HDAC6) through ternary complex formation and the ubiquitin-proteasome pathway, exhibiting a DC50 value of 19.4 nM. With IC50 values of 4.54 nM for HDAC6 and 0.647 μM for HDAC1, it effectively induces significant hyperacetylation of α-tubulin. This compound is valuable for research applications focused on neurodegenerative diseases and cancer, where modulation of HDAC6 activity may play a critical role. -
PROTAC HDAC Degrader
HD-TAC7 is a highly effective PROTAC HDAC degrader, specifically targeting histone deacetylases HDAC1, HDAC2, and HDAC3 with IC50 values of 3.6 μM, 4.2 μM, and 1.1 μM, respectively. This compound has demonstrated the ability to reduce NF-κB p65 levels in RAW 264.7 macrophages. HD-TAC7 is suitable for research applications focused on inflammatory diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
HDAC11 Inhibitor
TD034 is a selective, reversible, and noncovalent inhibitor of HDAC11, exhibiting an IC50 value of 5.1 nM and a Ki of 1.5 nM. This compound specifically targets HDAC11 without affecting other histone deacetylases or sirtuins, and it inhibits the defatty acylation of the substrate SHMT2. Additionally, TD034 reduces the levels of YAP1 through its action on HDAC11. This reagent is suitable for investigating the role of HDAC11 in lung cancer research. -
HDAC6/MAO-A/LSD1 Inhibitor
HDAC6-IN-3 is a potent inhibitor of histone deacetylase 6 (HDAC6), with an IC50 ranging from 0.02 to 1.54 μM for various HDAC isoforms, including HDAC1, HDAC2, HDAC3, and HDAC8. Additionally, it exhibits significant inhibitory activity against monoamine oxidase A (MAO-A) with an IC50 of 0.79 μM and lysine-specific demethylase 1 (LSD1). This compound serves as a valuable tool for research applications in cancer biology and epigenetics and is equipped with an alkyne functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
HDAC6 Inhibitor
HDAC6-IN-23 is a potent inhibitor of the histone deacetylase HDAC6, exhibiting oral bioavailability. This compound demonstrates significant biological activity by modulating histone acetylation, which plays a crucial role in gene regulation and cellular processes. It is primarily utilized in research focused on neurodegenerative disorders, cancer therapy, and the study of protein homeostasis. -
HDAC Ligand
HDAC Ligand-1 is a selective histone deacetylase (HDAC) ligand that serves as a valuable building block for the synthesis of PROTAC HDAC degraders. This compound can facilitate the development of innovative therapeutic agents targeting HDAC enzymes, enhancing the understanding of their role in various biological processes. Its applications extend to cancer research and epigenetic studies, providing insights into the modulation of gene expression and cellular behavior. -
HDAC6/10 Inhibitor
HDAC-IN-4 is a selective inhibitor of HDAC6 and HDAC10, demonstrating pIC50 values of 7.2 and 6.8 in BRET assays, respectively. This compound exhibits antitumoral activity, making it a significant tool for the investigation of cancer biology and the modulation of gene expression. Its selective inhibition of these histone deacetylases positions HDAC-IN-4 as a valuable reagent for research focusing on epigenetic regulation and potential therapeutic applications in cancer treatment. -
HDAC Inhibitor
BG48 is a potent histone deacetylase (HDAC) inhibitor that selectively targets HDAC1 and HDAC2. By inhibiting the enzymatic activity of these enzymes, BG48 modulates gene expression and can influence cellular processes such as differentiation, proliferation, and apoptosis. This compound is valuable for research applications in cancer biology, neurodegenerative diseases, and epigenetic studies. -
HDAC I/IIb Inhibitor
Purinostat is a selective inhibitor of histone deacetylases (HDAC) I and IIb, exhibiting potent anti-leukemic activity. It effectively reduces the survival of Philadelphia chromosome-positive leukemic cells and CD34+ leukemic progenitors from chronic myeloid leukemia patients. By targeting HDAC I/IIb, Purinostat disrupts critical pathways for leukemic stem cell survival, influencing factors such as c-Myc, β-Catenin, E2F, Ezh2, Alox5, and mTOR. Additionally, Purinostat enhances glutamate metabolism in leukemic stem cells by upregulating GLS1. -
HDAC Inhibitor
HNHA is a potent histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM. The compound effectively induces cell cycle arrest at the G1/S phase through the upregulation of p21. HNHA has demonstrated the ability to inhibit tumor growth and neovascularization, suggesting potential applications in cancer research, particularly in the context of breast cancer therapeutics. -
PROTAC HDAC Degrader
JPS036 is a benzamide-based HDAC degrader that operates through the Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC) mechanism. This compound selectively degrades class I histone deacetylases (HDAC1 and HDAC2), demonstrating significant biological activity by promoting the expression of differentially expressed genes and enhancing apoptosis in HCT116 cells. JPS036 serves as a valuable research tool for studying the roles of HDACs in cellular processes and disease models. -
HDAC Inhibitor
HDAC-IN-40 is a potent alkoxyamide-based inhibitor of histone deacetylases (HDACs), specifically targeting HDAC2 and HDAC6 with Ki values of 60 nM and 30 nM, respectively. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. HDAC-IN-40 can be utilized to explore the role of histone deacetylation in tumor development and progression, as well as to investigate potential therapeutic interventions in various cancers. -
HDAC1/2 Inhibitor
BG47 is a selective inhibitor of histone deacetylases HDAC1 and HDAC2, functioning as an optoepigenetic probe. Upon light-induced trans-to-cis isomerization, BG47 competitively inhibits the deacetylase activity of its targets, resulting in increased acetylation of Histone H3K9. This compound is relevant for research applications in neurological diseases, providing insights into epigenetic regulation and its implications in various disorders. -
HDAC6 Inhibirotr
HDAC6-IN-65 is a selective inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 0.9 nM, demonstrating additional inhibitory effects on HDAC3 with an IC50 of 39.4 nM. This compound induces the accumulation of acetylated α-tubulin and acetylated histone H3 in Neuro-2a cells, serving as a marker for class I HDAC inhibition. HDAC6-IN-65 provides valuable insights in the study of melanoma and related cancer research applications. -
Anti-inflammatory Agent
NPB-1575 is a potent, orally bioavailable anti-inflammatory agent that effectively targets neuroinflammation. It functions by activating the IRS2/Nrf2/NF-κB signaling axis, thereby combating ferroptosis and providing neuroprotection. NPB-1575 demonstrates efficacy in mitigating cerebral ischemic injury and enhancing neurological outcomes, making it a valuable tool for research focused on ischemic stroke and related neurodegenerative conditions. -
Ferroptosis Inhibitor
5-Hydroxy-6,7-dimethoxyflavone is a potent inhibitor of ferroptosis, acting primarily to mitigate H1N1 virus-induced cell death. This compound enhances the expression of SLC7A11 and GPX4, thereby providing protective effects against ferroptosis. Additionally, it reduces inflammatory responses and apoptosis by inhibiting the activation of NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone is valuable for research related to H1N1 influenza virus infection and ferroptosis regulation. -
HDAC Inhibitor
HDAC-IN-48 is a potent inhibitor of histone deacetylases (HDACs) that exhibits significant cytotoxicity, with a GI50 of approximately 20 nM. This hybrid molecule incorporates pharmacophores from SAHA and CETZOLE, effectively inducing ferroptosis while inhibiting HDAC activity. Additionally, HDAC-IN-48 features an alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, making it a valuable tool for click chemistry applications in chemical biology and therapeutic research.
